Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05777460
Recruiting Observational

Mid- and Long-term Outcomes of Custom-made Aortic Devices

NCT05777460 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Started
2020-10-01
Last updated
2025-03-18

Condition(s) studied

Aortic DiseasesThoracic Aortic Aneurysm

Investigational drug(s) / intervention(s)

Thoracic endovascular aortic repair (TEVAR)

Thoracic endovascular aortic repair (TEVAR): The TEVAR procedure involves the placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.

Study summary

This study aims to evaluate mid- and long-term outcomes after Thoracic endovascular aortic repair (TEVAR) with custom-made devices.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Thoracic Aortic Disease Exclusion Criteria: * Urgent/Emergent treatment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fondazione Policlinico Universitario A. Gemelli IRCCS Roma RM Recruiting

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

Ultrasound Monitoring of Muscle Thickness in Premature Patients Active, not recruiting
GCP-R3 Clinical Practice Survey in Research Centers Recruiting
Intracoronary Provocative Test With Acetylcholine in Patients With INOCA and MINOCA Recruiting
FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae Recruiting
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. Recruiting

Other trials for the same condition

Aortic Dissection fAlse enlarGement radIomics predictiOn Active, not recruiting
Use of Shockwave M5+/L6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access Recruiting
International Multicenter Mycotic Aneurysm Aorto-iliac Study Recruiting
Impact of Aortic Diseases on Quality of Life and Work Ability Recruiting
Zenith Thoracic Alpha (ZTA) Post-Market Data Collection Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05777460 on ClinicalTrials.gov ↗ ← All trials in Italy